Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mallya

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Matrix (Stuttgart, Germany). Supplement|January 1, 1992
Sulfur-based inhibitors for matrix metalloproteinasesM A Schwartz, S Venkataraman, A Libby, et al.
Journal of Endocrinological Investigation|December 18, 2022
Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetesM Vohra, A R Sharma, S Mallya, et al.
Bioorganic & Medicinal Chemistry|June 18, 1998
Exploration of the importance of the P2-P3-NHCO-moiety in a potent di- or tripeptide inhibitor of calpain I: insights into the development of nonpeptidic inhibitors of calpain IS Chatterjee, M Iqbal, S Mallya, et al.
Journal of Medicinal Chemistry|November 26, 1997
Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain IS Chatterjee, M A Ator, D Bozyczko-Coyne, et al.
Journal of Medicinal Chemistry|July 21, 1998
D-amino acid containing, high-affinity inhibitors of recombinant human calpain IS Chatterjee, Z Q Gu, D Dunn, et al.
The Journal of Clinical Investigation|May 9, 2001
Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic miceY Imanishi, Y Hosokawa, K Yoshimoto, et al.
Leukemia|October 24, 2012
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemiaM R Janes, C Vu, S Mallya, et al.
Pharmacogenomics|January 7, 2015
Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomesJennie G Pouget, Vanessa F Gonçalves, Erika L Nurmi, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Matrix (Stuttgart, Germany). Supplement|January 1, 1992
Sulfur-based inhibitors for matrix metalloproteinasesM A Schwartz, S Venkataraman, A Libby, et al.
Journal of Endocrinological Investigation|December 18, 2022
Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetesM Vohra, A R Sharma, S Mallya, et al.
Bioorganic & Medicinal Chemistry|June 18, 1998
Exploration of the importance of the P2-P3-NHCO-moiety in a potent di- or tripeptide inhibitor of calpain I: insights into the development of nonpeptidic inhibitors of calpain IS Chatterjee, M Iqbal, S Mallya, et al.
Journal of Medicinal Chemistry|November 26, 1997
Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain IS Chatterjee, M A Ator, D Bozyczko-Coyne, et al.
Journal of Medicinal Chemistry|July 21, 1998
D-amino acid containing, high-affinity inhibitors of recombinant human calpain IS Chatterjee, Z Q Gu, D Dunn, et al.
The Journal of Clinical Investigation|May 9, 2001
Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic miceY Imanishi, Y Hosokawa, K Yoshimoto, et al.
Leukemia|October 24, 2012
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemiaM R Janes, C Vu, S Mallya, et al.
Pharmacogenomics|January 7, 2015
Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomesJennie G Pouget, Vanessa F Gonçalves, Erika L Nurmi, et al.
Pageof 3